Table 1.
Outcomes of atrial fibrillation recurrence with anti-inflammatory therapies
| Study | Study type | Sample size | Intervention | Primary endpoint | Median follow-up | Effect estimate (95% CI) | Deduction |
|---|---|---|---|---|---|---|---|
| AF with canakinumab following cardioversion | |||||||
| Krisai et al, 2020 | Randomized controlled trial | 24 | Canakinumab | AF recurrence at 6 months | 6 months | HR: 0.36 (0.11; 1.15) | Neutral |
| AF with colchicine following surgery | |||||||
| Imazio et al, 2011 (COPPS) | Randomized controlled trial | 336 | Colchicine | Post-op AF at 1 month | 1 month | RR: 0.56 (0.34; 0.93) | Positive |
| Imazio et al, 2014 (COPPS-2) | Randomized controlled trial | 360 | Colchicine | Post-op AF within 3 months | 3 months | RR: 0.81 (0.62; 1.06) | Neutral |
| Tabbalat et al, 2016 | Randomized controlled trial | 360 | Colchicine | Post-op AF after 1 week | 8 days | RR: 0.71 (0.45; 1.12) | Neutral |
| Zarpelon et al, 2016 | Randomized controlled trial | 140 | Colchicine | Post-op AF after 2 weeks | 14 days | RR: 0.54 (0.19; 1.53) | Neutral |
| AF with corticosteroids following PVI/ablation | |||||||
| Koyoma et al, 2010 | Randomized controlled trial | 125 | Hydrocortisone and prednisolone | AF recurrence at 14 months | 14 months | HR: 0.45 (0.23; 0.93) | Positive |
| Won et al, 2013 | Prospective cohort study | 89 | Low-dose hydrocortisone | AF recurrence at 12 months | 12 months | RR: 0.65 (0.36; 1.20) | Neutral |
| Kim YR et al, 2015 | Randomized controlled trial | 138 | Methylprednisolone | AF recurrence at 3 months AF recurrence at 24 months |
3 months 24 months |
RR: 0.57 (0.35; 0.93) RR: 1.09 (0.69; 1.74) |
Positive Neutral |
| Kim DR et al, 2015 | Randomized controlled trial | 407 | Hydrocortisone and methylprednisolone | AF recurrence at 12 months | 12 months | RR: 0.92 (0.58; 1.45) | Neutral |
| Iskandar et al, 2017 | Randomized controlled trial | 60 | Prednisone | AF recurrence at 12 months | 12 months | RR: 1.33 (0.66; 2.69) | Neutral |
| AF with colchicine following PVI/ablation | |||||||
| Deftereos et al, 2012 | Randomized controlled trial | 170 | Colchicine | AF recurrence at 3 months | 3 months | RR: 0.47 (0.27; 0.85) | Positive |
| Egami et al, 2013 (Abstract) | Randomized controlled trial | 62 | Colchicine | AF recurrence at 2 weeks AF recurrence at 2 months |
2 weeks 2 months |
RR: 0.43 (0.19; 0.95) RR: 1.07 (0.23; 4.87) |
Positive Neutral |
| Deftereos et al, 2014 | Randomized controlled trial | 206 | Colchicine | AF recurrence at 12 months | 12 months | RR: 0.63 (0.44; 0.89) | Positive |
| Egami et al, 2015 (Abstract) | Prospective cohort study | 122 | Colchicine | AF recurrence at 12 months | 12 months | RR: 0.28 (0.11; 0.75) | Positive |
AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio; Post-op = postoperative; PVI = pulmonary vein isolation; RR = relative risk.